DOLK gene

Key red flags include unexplained dilated cardiomyopathy (weak, enlarged heart) in a child or young adult, developmental delays, seizures, or distinctive facial features. Laboratory clues are low serum transferrin isoelectric focusing patterns indicating hypoglycosylation, and imaging may show brain white‑matter changes. How is DOLK‑CDG diagnosed, and what tests are needed?::Diagnosis starts with a clinical suspicion, followed by a serum transferrin glyco‑analysis (isoelectric focusing) to detect abnormal glycosylation. Confirmation requires a DNA test for DOLK mutations, typically through targeted sequencing or whole‑exome sequencing. Functional studies of dolichol kinase activity can be done in specialized labs if needed. What treatments are available for the heart problems seen in DOLK‑CDG, and how often should cardiac monitoring occur?::Heart care follows standard dilated cardiomyopathy protocols: beta‑blockers, ACE inhibitors or ARBs, diuretics, and possibly anticoagulation if arrhythmias are present. Cardiac MRI or echocardiography should be performed at diagnosis and then every 6–12 months, or sooner if symptoms change, to track ventricular function and guide therapy. Can patients with DOLK‑CDG benefit from dietary or supplement interventions to improve glycosylation?::Currently, no specific diet or supplement reliably corrects the glycosylation defect. Some clinicians trial high‑dose vitamin B6 or choline, but evidence is limited. The focus remains on managing organ‑specific complications and supportive care; ongoing research may identify targeted therapies in the future.